Quick View
| Metric | Current Period | Same Period Previous Year | YoY |
|---|---|---|---|
| Revenue | - | - | - |
| Operating Income | - | - | - |
| Ordinary Income | ¥3.53B | ¥0.96B | +267.5% |
| Net Income | ¥2.43B | ¥0.65B | +274.3% |
| ROE | 8.3% | 2.2% | - |
Executive Summary
A substantial increase in revenue and profit was achieved, driven by improved underwriting profitability centered on the Non-Life Insurance Business and the recognition of gains on the sale of securities. Revenue (ordinary income from external customers) was ¥21.91B (¥18.24B in the previous year, +20.2%), Ordinary Income was ¥3.53B (¥0.96B in the previous year, +267.5%), and Net Income was ¥2.43B (¥0.65B in the previous year, +274.3%). The primary drivers of profit growth were the normalization of underwriting profitability and a sharp increase in investment income resulting from the recognition of ¥1.996B in gains on the sale of securities. It should be noted that the latter includes a temporary factor.
Factors Affecting Performance
【Revenue】Revenue was ¥21.91B, representing a year-on-year increase of +20.2%. The core Non-Life Insurance Business generated ¥19.51B (+20.9%) and accounted for approximately 89% of total revenue, driving the increase. The Animal Hospital Operations Business (+20.2%) and Health Innovation Business (+37.9%) also posted strong growth, while the Internet Services for Pets Business declined, with revenue of ¥0.58B (-2.7%).
【Profit and Loss】Ordinary Income increased substantially to ¥3.53B (¥0.96B in the previous year, +267.5%), while Net Income rose to ¥2.43B (¥0.65B in the previous year, +274.3%). Segment profit in the Non-Life Insurance Business surged to ¥3.73B (¥0.997B in the previous year), driving consolidated earnings. In contrast, the Animal Hospital Operations Business posted a loss of ¥0.19B (profit of ¥0.06B in the previous year), while the Health Innovation Business recorded an increased loss of ¥0.07B. Extraordinary losses were minimal at ¥0.01B, and the effective tax rate on Profit Before Tax of ¥3.52B was approximately 30.9%, within a normal range. The Company achieved higher revenue and profit, with a notable concentration of earnings in the Non-Life Insurance Business.
Segment Analysis
The Non-Life Insurance Business is the core business, accounting for the majority of consolidated earnings, with revenue of ¥19.51B (+20.9%) and profit of ¥3.73B (¥0.997B in the previous year, +274%). The Internet Services for Pets Business recorded revenue of ¥0.58B (-2.7%) and profit of ¥0.05B (¥0.084B in the previous year), representing a decline in profit. Despite revenue growth of +20.2% to ¥0.82B, the Animal Hospital Operations Business reported a loss of ¥0.19B, compared with a profit of ¥0.06B in the previous year. The Health Innovation Business grew revenue by +37.9% to ¥0.17B, but its loss expanded to ¥0.07B. The surrounding businesses have not converted revenue growth into profit, clearly indicating a structure in which earnings are concentrated in the Non-Life Insurance Business.
Key Financial Metrics
【Profitability】The Operating Income Margin was approximately 16.1% (Ordinary Income of ¥3.53B / Revenue of ¥21.91B), a substantial improvement from 5.3% in the previous year. The Net Profit Margin also improved to 11.1% from 3.6% in the previous year. These improvements were supported by an improvement in the loss ratio of the Non-Life Insurance Business (approximately 63%) and normalization of the combined ratio (in the 93% range). 【Cash Quality】Gains on the sale of securities of ¥1.996B made a significant contribution to the increase in Ordinary Income. It is important to note that recurring underwriting income and temporary investment income are combined in the results. 【Investment Efficiency】ROE was 8.3%, while the Equity Ratio was 38.6%. Although total asset turnover remained low, this reflects the business characteristics of an insurer carrying substantial insurance liabilities. 【Financial Soundness】The Equity Ratio was 38.6%. With total assets of ¥75.74B and net assets of ¥29.26B, the capital base remains stable. The balance of corporate bonds was ¥5.0B, indicating a moderate level of financial leverage.
Cash Flow Analysis
Although the Company does not disclose a statement of cash flows, changes in the balance sheet indicate that cash and deposits decreased to ¥10.59B from ¥13.39B in the same period of the previous year, while securities increased slightly to ¥43.32B, suggesting that a portion of funds may have shifted to investment assets. Retained earnings increased to ¥18.00B from ¥16.23B in the previous year, and the accumulation of current-period profit supported the strengthening of the capital base. Treasury stock increased to ¥1.49B from ¥1.00B in the same period of the previous year, suggesting that progress in share repurchases accounted for part of the use of funds. Outstanding policy reserves remained broadly flat at ¥28.81B, with no significant change in insurance liabilities observed.
Quality of Earnings
Current-period profit reflects both an improvement in recurring earnings power from enhanced underwriting profitability and the temporary factor of ¥1.996B in gains on the sale of securities. While recurring underwriting profit and interest and dividend income remained stable, gains on the sale of securities accounted for a high proportion of investment income (¥2.25B), leaving uncertainty regarding reproducibility in the following fiscal year and beyond. Unpaid claims increased to ¥4.35B from ¥4.12B in the previous year, indicating that reserving in line with claims incurred has been maintained. Extraordinary losses were minimal at ¥0.007B, and the difference between Ordinary Income and Net Income was primarily attributable to the tax burden. Comprehensive income was ¥1.47B, below Net Income of ¥2.43B, as other securities valuation difference declined to -¥0.96B, negatively affecting equity.
Earnings Forecast and Guidance
Against the full-year forecast of Ordinary Income of ¥5.00B, Net Income of ¥3.25B, and EPS of ¥44.43 yen, progress in Q1 was 70.6% for Ordinary Income and 74.9% for Net Income, substantially exceeding the simple benchmark of 25%. This high progress rate includes the temporary factor of gains on the sale of securities, and the pace of progress may slow from the second half onward as investment income normalizes. No revisions have been made to the earnings forecast or dividend forecast.
Shareholder Returns
The dividend forecast remains ¥13.5 per share, with no revisions. Based on the full-year Net Income forecast of ¥3.25B and the Company’s planned DPS, the Payout Ratio is approximately 30%. Retained earnings of ¥18.00B also provide a substantial internal reserve, supporting dividend sustainability. Treasury stock increased to ¥1.49B from ¥1.00B in the same period of the previous year, indicating progress in share repurchases; however, the Payout Ratio calculation uses only Net Income and dividends.
Risk Factors
-
Earnings concentration risk: The Non-Life Insurance Business accounts for the majority of Ordinary Income, while the surrounding businesses (Animal Hospital Operations and Health Innovation) remain in the red. Segment diversification is limited, and fluctuations in the profitability of the core business directly affect consolidated performance.
-
Temporary nature of investment income: Gains on the sale of securities of ¥1.996B, one factor behind the sharp increase in Ordinary Income, are temporary and account for a substantial portion of investment income of ¥2.25B in the quarter. There is no guarantee that a contribution at the same level will continue in the following fiscal year and beyond.
-
Deterioration in valuation differences on other securities: AOCI deteriorated by -¥9.65B year on year, increasing the volatility of equity due to market prices and interest-rate trends. Changes in unrealized gains and losses affect equity and comprehensive income.
Industry Benchmark (For Reference; Compiled by the Company)
No industry benchmark data available
Key Takeaways from the Financial Results
-
Improved underwriting profitability in the Non-Life Insurance Business drove consolidated earnings, and normalization of the combined ratio suggests an improvement in underlying earnings power. The expense ratio was approximately 30.8%, somewhat high, making progress in cost efficiency a focus going forward.
-
Full-year progress rates were high at 70.6% for Ordinary Income and 74.9% for Net Income; however, these figures include the temporary contribution from gains on the sale of securities, making it inappropriate to simply extrapolate them to the full-year results.
-
The Animal Hospital Operations Business and Health Innovation Business continue to report losses despite revenue growth, and progress in monetizing the surrounding businesses will determine the quality of consolidated earnings over the medium term.
This report is an earnings analysis document automatically generated by AI based on XBRL financial results summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available financial results data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
Anicom Holdings delivered an exceptionally strong FY2027 Q1 profit outcome, led by the core pet insurance business and a sharp increase in realized investment gains. Ordinary income rose 267.5% year on year to JPY3.53bn, while profit attributable to owners increased 274.0% to JPY2.43bn. External ordinary revenue increased 20.1% to JPY21.91bn. The core non-life insurance segment generated JPY19.51bn of external ordinary revenue, up 20.9%, and segment profit of JPY3.73bn, up from JPY1.00bn a year earlier. The core segment accounted for more than 100% of consolidated segment profit, offsetting losses in the animal hospital and health innovation businesses. Net premiums written grew 5.9% to JPY16.71bn, providing evidence of continued underlying policy growth. Underwriting income increased 9.1% to JPY17.22bn, while operating expenses rose 6.4% to JPY18.38bn. This positive spread between underwriting-income growth and expense growth supported a substantially improved insurance profit profile. Investment income surged to JPY2.25bn from JPY0.36bn, including JPY2.00bn of gains on sales of securities versus JPY0.15bn in the prior-year quarter. Consequently, the 11.1% net margin and annualized return metrics materially overstate recurring underwriting profitability. The effective tax rate was 30.9%, and the tax burden of 0.691 was broadly consistent with the reported tax charge. Net income of JPY2.43bn exceeded comprehensive income of JPY1.47bn because securities valuation losses reduced other comprehensive income by JPY0.96bn. The unchanged full-year ordinary-income forecast of JPY5.00bn has already been reached by 70.6% in Q1, indicating that management is either conservative or expects a normalization in investment gains and/or insurance profitability through the remainder of the year. Q1 net income represents 74.9% of the JPY3.25bn full-year forecast. The investment case therefore hinges on separating recurring premium and underwriting improvement from volatile realized and unrealized securities performance. Capital remains supported by equity of JPY29.26bn, but the investment portfolio and reserve liabilities make market movements and claims trends central variables for subsequent quarters.
Profitability Analysis
Using annualized Q1 flows and average balance-sheet values, DuPont ROE is approximately 33.4%, comprising an 11.1% net profit margin, roughly 1.15x annualized asset turnover, and approximately 2.62x financial leverage. The largest year-on-year driver was the net margin: net income increased 274.0%, far faster than the 20.1% increase in external ordinary revenue. The core non-life insurance business was the principal operating contributor, with segment profit expanding by JPY2.73bn to JPY3.73bn. Its segment margin improved from 6.2% to 19.1%, an expansion of about 1,290 basis points. By contrast, pet-oriented internet services saw revenue decline 2.7% to JPY0.58bn and segment profit decline 45.2% to JPY0.46bn, reducing its margin from 14.1% to 7.9%. Animal hospital operations increased revenue by 20.2% to JPY0.82bn but moved from a JPY0.60bn profit to a JPY1.91bn loss. Health innovation revenue rose 37.9% to JPY0.17bn, while its loss widened from JPY0.61bn to JPY0.74bn. The other-business category improved from a JPY0.12bn loss to a JPY0.24bn profit on 18.9% revenue growth. Underwriting income growth of 9.1% exceeded the 6.4% rise in operating expenses, indicating favorable operating leverage within insurance operations. However, JPY2.00bn of gains on sales of securities was a major contributor to investment income, so the quarter's reported profit expansion should not be treated as fully recurring. The reported interest burden of 0.998 indicates that interest expense was immaterial relative to pre-tax earnings. The tax burden of 0.691 was modestly below the 0.70 reference point, reflecting the 30.9% effective tax rate. Annualized ROA is approximately 12.8%, but it is similarly elevated by securities-sale gains. JGAAP goodwill amortization was JPY0.64bn during the quarter, which depresses reported operating and net profit relative to an IFRS reporter, although it was not large enough to explain the scale of the quarter-on-quarter profit improvement.
Growth Assessment
Revenue growth was led by the non-life insurance segment, where external ordinary revenue increased JPY3.37bn year on year to JPY19.51bn. Net premiums written rose to JPY16.71bn from JPY15.78bn, a 5.9% increase, indicating that the underlying insurance franchise continued to expand even though premium growth lagged segment ordinary-revenue growth. The stronger segment profit suggests improved pricing, claims experience, expense absorption, investment contribution, or a combination of these factors. Underwriting income increased by JPY1.44bn, whereas operating expenses increased by JPY1.10bn, leaving a JPY0.33bn improvement in the operating spread before considering the much larger investment-income uplift. Investment income rose by JPY1.89bn year on year, principally reflecting JPY2.00bn of securities-sale gains. This means the earnings growth rate is substantially less sustainable than the revenue growth rate. The animal hospital segment's deterioration is a material drag on diversification benefits, as higher revenue did not translate into profitability. The internet services segment remains profitable but its revenue and margin trends weakened. The company maintained its full-year ordinary-income forecast of JPY5.00bn despite Q1 progress of 70.6%, which is 45.6 percentage points ahead of the standard 25% Q1 progress rate. Net-income progress is also 49.9 percentage points above the standard pace, at 74.9% of the full-year forecast. Such front-loading is consistent with a realized investment gain that may not recur evenly. Management's unchanged forecast therefore implies substantial expected moderation after Q1. Goodwill declined to JPY2.10bn from JPY2.36bn, reflecting amortization rather than a new material acquisition-led expansion. Goodwill equals about 7.1% of total equity, a contained level that limits balance-sheet dependence on acquired business values.
Financial Health
Total assets were JPY75.74bn, total liabilities JPY46.48bn, and total equity JPY29.26bn. Equity increased by JPY0.32bn year on year despite JPY0.96bn of other comprehensive loss, demonstrating that retained earnings growth more than offset securities valuation pressure. Retained earnings increased 10.9% to JPY18.00bn. Total liabilities declined by JPY1.27bn year on year, while total assets declined by JPY0.95bn. The reported debt-to-equity ratio was 1.59x, below the 2.0x aggressive-leverage warning threshold. For an insurer, this ratio includes substantial policyholder and insurance-reserve liabilities and is therefore less indicative of financial debt risk than for an industrial company. Interest-bearing bonds payable were JPY5.00bn, equivalent to about 17.1% of total equity, while interest expense was only JPY0.03bn in Q1. Insurance policy liability reserves were JPY28.81bn, and outstanding claims were JPY4.35bn; reserve adequacy and claims development are consequently more relevant solvency variables than conventional short-term debt metrics. Cash and deposits were JPY10.59bn and securities were JPY43.32bn, with securities representing 57.2% of total assets. This asset mix provides a large investment base but creates sensitivity to equity, bond, and interest-rate market movements. Securities valuation differences within equity deteriorated to negative JPY2.57bn from negative JPY1.61bn, and Q1 other comprehensive loss was JPY0.96bn. Treasury stock increased in magnitude by JPY0.49bn to negative JPY1.49bn, a 48.6% change that reduced reported equity but signals active capital management. Intangible assets were JPY3.73bn, or 4.9% of assets, well below the level associated with elevated intangible-asset concentration. Property, plant and equipment increased to JPY6.96bn from JPY6.42bn, consistent with continued investment in operating infrastructure, including the animal-hospital platform.
Notable B/S Changes
Treasury stock: increased in magnitude by JPY0.49bn to negative JPY1.49bn (-48.6%) - reduced equity but indicates active capital management and should be assessed alongside dividends and insurance capital needs. Retained earnings: increased by JPY1.77bn to JPY18.00bn (+10.9%) - Q1 profitability strengthened the internal capital base despite adverse securities valuation movements. Securities valuation difference: deteriorated by JPY0.97bn to negative JPY2.57bn - market-value losses reduced accumulated other comprehensive income and highlight portfolio-market sensitivity. Goodwill: declined by JPY0.26bn to JPY2.10bn (-10.9%) - reflects ongoing JGAAP amortization; goodwill remains modest at approximately 7.1% of equity. Property, plant and equipment: increased by JPY0.54bn to JPY6.96bn (+8.4%) - continued fixed-asset investment should be monitored against the profitability of the animal-hospital platform.
Cash Flow Quality
Reported Q1 profit quality is mixed from an economic perspective because a material portion of earnings arose from securities sales rather than solely recurring insurance operations. Investment income was JPY2.25bn, up JPY1.89bn year on year, and included JPY2.00bn of realized gains on sales of securities. These gains support cash realization when settled, but they depend on portfolio transactions and available unrealized gains rather than recurring underwriting performance. The core insurance business nevertheless showed positive operating leverage, as underwriting income growth exceeded operating-expense growth. Net income of JPY2.43bn was materially above comprehensive income of JPY1.47bn because JPY0.96bn of valuation losses on securities passed through other comprehensive income. This divergence illustrates that realized gains recognized in profit were accompanied by unfavorable fair-value movements in the remaining securities portfolio. The securities portfolio of JPY43.32bn remains large relative to equity, so future realized and unrealized investment results may be volatile. The JPY0.64bn quarterly goodwill amortization is a non-cash JGAAP expense and reduces accounting earnings without an equivalent current-period cash outflow. Insurance cash generation should also be assessed through premium collection, claims payments, reserve movements, and investment cash flows rather than net income alone. Net premiums written rose 5.9%, while net loss paid increased 13.6% to JPY9.95bn and the outstanding-claims provision declined to JPY0.23bn from JPY0.40bn. The faster growth in paid claims than premiums warrants continued monitoring, although Q1 ordinary profit demonstrates that the overall insurance result improved.
Dividend Sustainability
The full-year dividend forecast is JPY13.50 per share, unchanged from the company's announced plan. Against forecast EPS of JPY44.43, the implied dividend-only payout ratio is approximately 30.4%. This is comfortably below the 60% sustainability reference point. Q1 EPS was JPY33.09, meaning first-quarter earnings alone equaled about 74% of full-year forecast EPS. The annual dividend is therefore covered by Q1 reported EPS by approximately 2.45x, although Q1 earnings benefited substantially from realized securities gains. Retained earnings of JPY18.00bn provide a meaningful internal capital base for distributions after allowing for insurance capital requirements. The increase in treasury stock to negative JPY1.49bn indicates that capital returns or share-related capital management also affected equity; where buybacks are involved, total return ratio rather than dividend payout ratio is the appropriate broader measure. The stated dividend payout ratio remains the more conservative and relevant indicator for recurring cash distributions. Dividend sustainability should ultimately be judged against recurring underwriting profit, claims trends, regulatory capital needs, and the volatility of the securities portfolio rather than the unusually strong Q1 net income alone.
Risk Assessment
Business risks include Claims-cost risk: net loss paid increased 13.6% year on year to JPY9.95bn, faster than the 5.9% rise in net premiums written. Medical-cost inflation, higher utilization of veterinary services, or adverse pet-health claims frequency could pressure underwriting profitability., Core-business concentration: the non-life insurance segment produced JPY3.73bn of profit, more than consolidated segment profit, so group earnings remain overwhelmingly dependent on the pet insurance franchise., Non-core execution risk: the animal hospital business recorded a JPY1.91bn segment loss despite 20.2% revenue growth, while health innovation recorded a JPY0.74bn loss. Persistent losses could consume capital and dilute group returns., Pet insurance market risk: competition, policyholder retention, premium-rate acceptance, and veterinary-cost inflation can affect growth and loss experience in the company's core market..
Financial risks include Investment-market risk: securities totaled JPY43.32bn, or 57.2% of assets, and valuation losses generated JPY0.96bn of other comprehensive loss in Q1., Earnings volatility risk: JPY2.00bn of gains on sales of securities was a major contributor to the JPY2.25bn investment-income result, making quarterly profit sensitive to portfolio realization activity., Insurance liability and reserve risk: insurance policy liability reserves of JPY28.81bn and outstanding claims of JPY4.35bn require disciplined reserving and asset-liability management., Capital-management risk: treasury stock increased by JPY0.49bn year on year, reducing equity available to absorb insurance and market volatility..
Key concerns include The unchanged full-year ordinary-income forecast implies a sharp slowdown after Q1; ordinary-income progress of 70.6% is far above the normal 25% first-quarter pace., Comprehensive income of JPY1.47bn was 39.7% below net income of JPY2.43bn, demonstrating that securities valuation losses offset a meaningful portion of reported profit at the equity level., The sharp loss expansion in animal hospital operations is the most significant operating concern outside the core insurance business., JGAAP goodwill amortization of JPY0.64bn per quarter is recurring, although the remaining JPY2.10bn goodwill balance is modest relative to equity..
Investment Implications
Key takeaways include Core non-life insurance revenue grew 20.9% and segment profit rose to JPY3.73bn, confirming a major improvement in the principal earnings engine., The reported 274.0% increase in net income was not wholly operational: JPY2.00bn of gains on sales of securities was a major contributor., The full-year forecast remains unchanged despite Q1 ordinary-income progress of 70.6%, implying management expects a substantial moderation in subsequent quarters., The group has a manageable conventional debt burden, but insurance reserves and a securities portfolio equal to 57.2% of assets make claims performance and financial markets the key balance-sheet sensitivities., The animal hospital segment's JPY1.91bn loss limits the diversification value of the broader pet-health ecosystem..
Metrics to watch include Net premiums written growth versus net loss paid growth, Core non-life insurance segment margin and profit contribution, Realized gains and losses on securities, investment income, and securities valuation differences, Quarterly progress against the JPY5.00bn ordinary-income and JPY3.25bn net-income forecasts, Animal hospital segment loss trajectory and path to operating leverage, Insurance policy liability reserves, outstanding claims, and regulatory capital resilience, Treasury stock movements and the relationship between dividends, buybacks, and recurring earnings.
Regarding relative positioning, Anicom's Q1 profile combines high-growth pet-insurance operating momentum with meaningful investment-income sensitivity. Its 19.1% core non-life segment margin and annualized 33.4% ROE appear strong, but comparison with insurers should emphasize recurring underwriting performance, claims-cost discipline, reserve strength, and investment-market exposure because realized securities gains materially amplified reported profitability.